Relmada Therapeutics Launches $100M Stock Offering at $2.20 per Share

Relmada Therapeutics Inc. launched a $100 million stock offering priced at $2.20 per share, aimed at advancing its clinical-stage biotechnology projects.

Relmada Therapeutics Inc. (NASDAQ: RLMD) announced an underwritten offering of 40.14 million shares of common stock, priced at $2.20 per share.
The offering also includes pre-funded warrants to purchase up to 5.32 million shares, priced at $2.199 per pre-funded warrant.
Gross proceeds from this transaction are expected to be approximately $100 million, before expenses and underwriting discounts, as filed with the U.S. Securities and Exchange Commission.

Por Qué Es Relevante

This stock offering is significant as it provides Relmada Therapeutics with crucial funding to support its biotechnology initiatives, reflecting investor confidence in its pipeline. The successful execution may influence market trends in the biotech sector, especially among clinical-stage companies.